NBRV Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 liep. 2023 @ 23:00):

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections...

Stats
Šios dienos apimtis	706 536
Vidutinė apimtis	13 843.00
Rinkos kapitalizacija	4.55M
EPS	$-4.50 ( 2023-08-10 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0722
ATR14	$0.181 (28.73%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-06	Hogan H Michael Iii	Buy	0
2023-06-30	Maggio David	Buy	0
2023-01-29	Gelone Steven P.	Sell	140	Ordinary Shares
2023-01-29	Schroeder Theodore R	Sell	431	Ordinary Shares
2023-01-06	Gelone Steven P.	Sell	5	Ordinary Shares

INSIDER POWER
20.49
Last 98 transactions
Buy: 1 927 900 \| Sell: 612 376

Tūris Koreliacija

Ilgas: 0.06 (neutral)

Trumpas: 0.60 (weak)

Signal:(34.114) Neutral

Nabriva Therapeutics PLC Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Nabriva Therapeutics PLC Koreliacija - Valiuta/Žaliavos

-0.12
( neutral )

-0.25
( neutral )

-0.15
( neutral )

-0.11
( neutral )

0.79
( moderate )

0.14
( neutral )

Nabriva Therapeutics PLC Finansinės ataskaitos

Annual	2022
Pajamos:	$35.67M
Bruto pelnas:	$7.09M (19.87 %)
EPS:	$-21.32

FY	2022
Pajamos:	$35.67M
Bruto pelnas:	$7.09M (19.87 %)
EPS:	$-21.32

FY	2021
Pajamos:	$28.90M
Bruto pelnas:	$15.75M (54.50 %)
EPS:	$-96.24

FY	2020
Pajamos:	$2.86M
Bruto pelnas:	$2.10M (73.25 %)
EPS:	$-135.23

Financial Reports:

No articles found.

Nabriva Therapeutics PLC

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.